Abstract | BACKGROUND: MATERIALS AND METHODS: Articles and reviews found in PubMed and reference books were evaluated and compared to each other. RESULTS: Many treatment options exist. Current treatment options include paracentesis, intraperitoneal chemotherapy and therapy using intraperitoneal tumor necrosis factor alpha for example. Compared to other reviews, catumaxomab, a new antibody, was presented and the treatment options were focused on ovarian carcinoma patients. All these methods are palliative. CONCLUSION: The treatment of malignant ascites keeps a demanding difficulty and requires further study especially on progressive free survival and overall survival. Paracentesis and systemic therapy with a later effect are recommended at the moment. Catumaxomab is the only medication that could achieve an improvement.
|
Authors | Hannah Woopen, Jalid Sehouli |
Journal | Anticancer research
(Anticancer Res)
Vol. 29
Issue 8
Pg. 3353-9
(Aug 2009)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 19661355
(Publication Type: Journal Article)
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Ascites
(etiology, therapy)
- Female
- Humans
- Injections, Intraperitoneal
- Ovarian Neoplasms
(complications, drug therapy, surgery)
- Palliative Care
- Paracentesis
- Peritoneal Neoplasms
(drug therapy, secondary, surgery)
|